Ann: Operational Update-PYC.AX, page-31

I also remember the thread in September 2015 when we discussed the work of Dr Tatjana Heinrich from Phylogica. But first, Genentech has proven that some bacteria are able to escape antibiotics by hiding inside cells. Once the antibiotic course is complete they are able to reinfect the patient. It appeared for all money that bacteria had become resistant to antibiotics and had become superbugs whereas some bacteria just became very good at hiding. The chase is on.

Classes of antibiotics whose potency has been nullified by resistance may still work, but it would appear from Genentech's research, they will have to go intracellular.

Back to the September 2015 discussion. The comment was made that;
If Phylogica through its intracellular trap technology can overcome the inherent problem of poor permeability of traditional antibiotics then it could lead to the rejuvenation of the current classes of antibiotics.

Don O'Sullivan makes the point in the interview which you linked, that Genentech are also targeting gram negative bacteria, "looking for antibodies against those bacteria, we're looking for novel very highly potent antibiotics that we can conjugate to the antibodies". Note: Methicillin-Resistant Staphylococcus aureus (MRSA) is gram positive.

Dr Heinrich's expertise is antibiotic resistance in gram negative bacteria and the application of Phylogica's intracellular trap technology to the discovery of novel antimicrobial peptides. More directly her project teams research led to the Research and Licensing agreement with Genentech to discover novel antibiotics. Phylogica is developing a type of antibiotic, an antimicrobial peptide which is capable of combating 'superbugs’ like the gram negative multi-drug resistant Acinetobacter baumannii or Pseudomonas aeruginosa.

So where are we going with this discussion? Up a tree, nowhere or linking into the next collaboration with Genentech!